机译:使用Toca 511 + Toca FC治疗的一些复发性高级别胶质瘤患者的持久完全反应
Univ Calif Los Angeles, Dept Neurooncol, Los Angeles, CA USA;
JFK Brain Tumor Ctr, New Jersey Neurosci Inst, Edison, NJ USA;
Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA;
Tocagen Inc, San Diego, CA USA;
Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA;
JFK Brain Tumor Ctr, New Jersey Neurosci Inst, Edison, NJ USA;
Univ Calif San Diego, Moores Canc Ctr, Dept Neurosci, San Diego, CA 92103 USA;
Univ Calif San Diego, Moores Canc Ctr, Dept Neurosci, San Diego, CA 92103 USA;
Henry Ford Hosp, Detroit, MI 48202 USA;
Univ Calif San Diego, Moores Canc Ctr, Dept Neurosci, San Diego, CA 92103 USA;
Univ Calif Los Angeles, Dept Neurooncol, Los Angeles, CA USA;
Henry Ford Hosp, Detroit, MI 48202 USA;
Univ Calif Los Angeles, Dept Neurooncol, Los Angeles, CA USA;
Henry Ford Hosp, Detroit, MI 48202 USA;
Univ Calif Los Angeles, Dept Neurooncol, Los Angeles, CA USA;
Univ Calif San Diego, Moores Canc Ctr, Dept Neurosci, San Diego, CA 92103 USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Tocagen Inc, San Diego, CA USA;
Henry Ford Hosp, Detroit, MI 48202 USA;
durable response rate; gene therapy; immuno-oncology; immunotherapy; recurrent high grade glioma;
机译:来自TOCA 511和TOCA FC的三个第1阶段试验的126例复发性高度胶质瘤患者的长期随访数据:第2/3阶段试验的更新和合理性
机译:来自TOCA 511和TOCA FC三阶段1阶段的123名患者的长期随访数据来自TOCA 511和TOCA FC的三阶段试验:2/3阶段试验的更新和理由
机译:TOCA 511和TOCA FC的早期临床试验表明了对复发性恶性胶质瘤的有希望的新待遇
机译:TOCA-511基因治疗临床试验更新
机译:在职治疗:患者对工作场所初级保健服务受到冲击的反应。
机译:使用Toca 511 + Toca FC治疗的一些复发性高级别胶质瘤患者的持久完全反应
机译:ATIM-02。用TOCA 511和TOCA治疗,在IDH1野生型和突变体复发高级胶质瘤(RHGG)中观察到耐用的反应